Omeros - Public Comps and Valuation Multiples

Omeros Overview

About Omeros

Omeros Corp is a United States-based clinical-stage biopharmaceutical company engaged in discovering, developing, and commercializing small-molecule and protein therapeutics for large-market as well as orphan indications targeting immunologic disorders including complement-mediated diseases, cancers, and addictive and compulsive disorders. The lead drug candidate in the pipeline of complement-targeted therapeutics is narsoplimab (OMS721), a proprietary, patented human monoclonal antibody targeting mannan-binding lectin-associated serine protease 2, the key activator of the lectin pathway of complement. Clinical development of narsoplimab is currently focused on hematopoietic stem cell transplant-associated thrombotic microangiopathy and immunoglobulin nephropathy.

Founded

1994

HQ

Employees

202

Website

omeros.com

Sectors

Drug Development & Therapeutics
BioTech

Financials

LTM Revenue $1.0M

LTM EBITDA n/a

EV

$523M

Valuation Multiples

Multiples.vc

Valuation Multiples for 10K+ Public Comps

Benchmark forward-looking revenue and EBITDA valuation multiples across generative AI, climate tech, semiconductors, online marketplaces, vertical SaaS and 220 more verticals.

Browse Valuation Multiples

Omeros Financials

Omeros has a last 12-month revenue of $1.0M and a last 12-month EBITDA of n/a.

In the most recent fiscal year, Omeros achieved revenue of n/a and an EBITDA of -$157M.

Omeros expects next 12-month revenue of XXX and NTM EBITDA of XXX

See Omeros valuation multiples based on analyst estimates

Omeros P&L

	FY 2023	FY 2024	FY 2025	LTM	NTM
Revenue	n/a	n/a	XXX	XXX	XXX
Gross Profit	n/a	n/a	XXX	XXX	XXX
Gross Margin	NaN%	NaN%	XXX	XXX	XXX
EBITDA	-$143M	-$157M	XXX	XXX	XXX
EBITDA Margin	-Infinity%	-Infinity%	XXX	XXX	XXX
Net Profit	$47.4M	-$118M	XXX	XXX	XXX
Net Margin	Infinity%	-Infinity%	XXX	XXX	XXX
Net Debt	$304M	$206M	XXX	XXX	XXX

Financial data powered by Morningstar, Inc.

Omeros Stock Performance

As of April 15, 2025, Omeros's stock price is $7.

Omeros has current market cap of $406M, and EV of $523M.

See Omeros trading valuation data

Omeros Stock Data

EV	Market Cap	Price 1D	Price 1M	Price 3M	Price 12M	EPS
$523M	$406M	XXX	XXX	XXX	XXX	$-2.63

Benchmark Trading Valuation Multiples by Industry

Sign up to access valuation multiples like growth-adjusted P/E, next 12-month EV/Revenue, EBITDA multiples by industry and many more

Omeros Valuation Multiples

As of April 15, 2025, Omeros has market cap of $406M and EV of $523M.

Omeros's trades at 510.4x LTM EV/Revenue multiple, and n/a LTM EBITDA.

Analysts estimate Omeros's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See valuation multiples for Omeros and 10K+ public comps

Omeros Financial Valuation Multiples

	FY 2024	FY 2025E	FY 2026E	FY 2027E
EV	$523M	XXX	XXX	XXX
EV/Revenue	n/a	XXX	XXX	XXX
EV/EBITDA	-3.3x	XXX	XXX	XXX
P/E	-2.6x	XXX	XXX	XXX
P/E/Growth	n/a	XXX	XXX	XXX
EV/FCF	-3.5x	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Get Omeros Valuation Multiples

Access all public comps and forward-looking valuation multiples like EV/Revenue in 2025, based on equity research analyst estimates.

Omeros Valuation Multiples

Omeros's NTM/LTM revenue growth is 3481%

Omeros's revenue per employee for the last fiscal year averaged n/a, while opex per employee averaged $0.8M for the same period.

Over next 12 months, Omeros's ratio of sales and marketing spend to revenue is estimated to be XXX , while its R&D spend to revenue to be XXX .

Analysts estimate Omeros's 2025E EV/Revenue multiple at XXX and 2025E EV/EBITDA multiple at XXX

See operational valuation multiples for Omeros and other 10K+ public comps

Omeros Operational Valuation Multiples

	FY 2024	NTM	FY 2025E	FY 2026E	FY 2027E
Revenue Growth	n/a	XXX	XXX	XXX	XXX
EBITDA Margin	n/a	XXX	XXX	XXX	XXX
EBITDA Growth	10%	XXX	XXX	XXX	XXX
Rule of 40 (SaaS-only)	n/a	XXX	XXX	XXX	XXX
Revenue per Employee	n/a	XXX	XXX	XXX	XXX
Opex per Employee	$0.8M	XXX	XXX	XXX	XXX
S&M Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
G&A Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
R&D Expenses to Revenue	n/a	XXX	XXX	XXX	XXX
Opex to Revenue	n/a	XXX	XXX	XXX	XXX

Valuation data powered by FactSet, Inc. and Morningstar, Inc.

Valuation Multiples Across 220+ Verticals

Benchmark public comps and private revenue and EBITDA valuation multiples across GRC software, cloud infrastructure, DevOps, online marketplaces and so much more!

Digital Therapeutics

Pharma Analytics

Private Equity

ERP Software

Developer Tools

Consumer SaaS

Streaming Platforms

Explore Valuation Multiples by Industry